Adaptimmune Therapeutics Ownership 2024 | Who Owns Adaptimmune Therapeutics Now?
Institutional Ownership
63.46%
Insider Ownership
0.38%
Retail Ownership
36.16%
Institutional Holders
75.00
Adaptimmune Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| MATRIX CAPITAL MANAGEMENT COMPANY, LP | 16.11% | 0.29% | 38,974,185 | - | - | 37,995,933 | Jun 30, 2024 |
| ECOR1 CAPITAL, LLC | 11.33% | 0.82% | 27,404,070 | - | - | 26,716,228 | Jun 30, 2024 |
| NEA MANAGEMENT COMPANY, LLC | 7.06% | 1.25% | 17,079,778 | - | - | 16,651,076 | Jun 30, 2024 |
| BAILLIE GIFFORD & CO | 6.26% | 0.01% | 15,149,203 | -722,672 | -4.55% | 14,768,958 | Jun 30, 2024 |
| LONG FOCUS CAPITAL MANAGEMENT, LLC | 5.10% | 0.46% | 12,346,417 | 1,662,184 | 15.56% | 12,036,522 | Jun 30, 2024 |
| PFM HEALTH SCIENCES, LP | 4.35% | 0.51% | 10,520,231 | 97,096 | 0.93% | 10,256,173 | Jun 30, 2024 |
| MPM ASSET MANAGEMENT LLC | 2.30% | 2.97% | 5,555,461 | - | - | 5,416,574 | Jun 30, 2024 |
| BIOIMPACT CAPITAL LLC | 2.11% | 0.77% | 5,095,912 | - | - | 4,968,514 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 1.92% | 0.00% | 4,653,325 | -14,462 | -0.31% | 4,532,338 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 1.00% | 0.07% | 2,425,468 | - | - | 2,364,589 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 0.97% | 0.03% | 2,343,695 | -8,443,327 | -78.27% | 2,284,868 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.74% | 0.00% | 1,786,341 | 394,566 | 28.35% | 1,741,502 | Jun 30, 2024 |
| TANG CAPITAL MANAGEMENT LLC | 0.72% | 0.17% | 1,743,619 | 300,000 | 20.78% | 1,699,854 | Jun 30, 2024 |
| FMR LLC | 0.70% | 0.00% | 1,690,481 | -42,084 | -2.43% | 1,648,050 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.43% | 0.00% | 1,037,238 | 122,208 | 13.36% | 1,011,203 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.32% | 0.00% | 779,615 | -45,564 | -5.52% | 760,047 | Jun 30, 2024 |
| REDMILE GROUP, LLC | 0.30% | 0.04% | 715,607 | - | - | 697,645 | Jun 30, 2024 |
| ACUITAS INVESTMENTS, LLC | 0.22% | 0.28% | 541,201 | 2,880 | 0.54% | 527,617 | Jun 30, 2024 |
| MORGAN STANLEY | 0.18% | - | 440,832 | 67,551 | 18.10% | 429,768 | Jun 30, 2024 |
| RATHBONES GROUP PLC | 0.18% | 0.00% | 432,818 | - | - | 421,954 | Jun 30, 2024 |
Adaptimmune Therapeutics's largest institutional shareholder is MATRIX CAPITAL MANAGEMENT COMPANY, LP, holding 16.11% of the company's total share outstanding, currently valued at $38.00M. The top 10 institutional shareholders own together 57.55% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 2.30% | 2.97% | 5,555,461 | - | - | 5,416,574 | Jun 30, 2024 |
| NEA MANAGEMENT COMPANY, LLC | 7.06% | 1.25% | 17,079,778 | - | - | 16,651,076 | Jun 30, 2024 |
| ECOR1 CAPITAL, LLC | 11.33% | 0.82% | 27,404,070 | - | - | 26,716,228 | Jun 30, 2024 |
| BIOIMPACT CAPITAL LLC | 2.11% | 0.77% | 5,095,912 | - | - | 4,968,514 | Jun 30, 2024 |
| PFM HEALTH SCIENCES, LP | 4.35% | 0.51% | 10,520,231 | 97,096 | 0.93% | 10,256,173 | Jun 30, 2024 |
| LONG FOCUS CAPITAL MANAGEMENT, LLC | 5.10% | 0.46% | 12,346,417 | 1,662,184 | 15.56% | 12,036,522 | Jun 30, 2024 |
| MATRIX CAPITAL MANAGEMENT COMPANY, LP | 16.11% | 0.29% | 38,974,185 | - | - | 37,995,933 | Jun 30, 2024 |
| ACUITAS INVESTMENTS, LLC | 0.22% | 0.28% | 541,201 | 2,880 | 0.54% | 527,617 | Jun 30, 2024 |
| TANG CAPITAL MANAGEMENT LLC | 0.72% | 0.17% | 1,743,619 | 300,000 | 20.78% | 1,699,854 | Jun 30, 2024 |
| KEY CLIENT FIDUCIARY ADVISORS, LLC | 0.11% | 0.13% | 263,989 | -4,666 | -1.74% | 257,363 | Jun 30, 2024 |
| DAFNA CAPITAL MANAGEMENT LLC | 0.14% | 0.08% | 341,064 | - | - | 332,503 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 1.00% | 0.07% | 2,425,468 | - | - | 2,364,589 | Jun 30, 2024 |
| REDMILE GROUP, LLC | 0.30% | 0.04% | 715,607 | - | - | 697,645 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 0.97% | 0.03% | 2,343,695 | -8,443,327 | -78.27% | 2,284,868 | Jun 30, 2024 |
| COLUMBIA ADVISORY PARTNERS LLC | 0.01% | 0.03% | 28,087 | 12,502 | 80.22% | 27,382 | Jun 30, 2024 |
| MARQUETTE ASSET MANAGEMENT, LLC | 0.04% | 0.02% | 98,589 | - | - | 96,115 | Jun 30, 2024 |
| PROSPERITY WEALTH MANAGEMENT, INC. | 0.01% | 0.01% | 26,620 | - | - | 25,952 | Jun 30, 2024 |
| DLK INVESTMENT MANAGEMENT, LLC | 0.01% | 0.01% | 30,512 | - | - | 29,746 | Jun 30, 2024 |
| BAILLIE GIFFORD & CO | 6.26% | 0.01% | 15,149,203 | -722,672 | -4.55% | 14,768,958 | Jun 30, 2024 |
| WETZEL INVESTMENT ADVISORS, INC. | 0.00% | 0.01% | 6,000 | - | - | 9,480 | Jun 30, 2024 |
The largest Adaptimmune Therapeutics shareholder by % of total assets is MPM ASSET MANAGEMENT LLC. The company owns 5.56M shares of Adaptimmune Therapeutics (ADAP), representing 2.97% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| LONG FOCUS CAPITAL MANAGEMENT, LLC | 5.10% | 0.46% | 12,346,417 | 1,662,184 | 15.56% | 12,036,522 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.74% | 0.00% | 1,786,341 | 394,566 | 28.35% | 1,741,502 | Jun 30, 2024 |
| TANG CAPITAL MANAGEMENT LLC | 0.72% | 0.17% | 1,743,619 | 300,000 | 20.78% | 1,699,854 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.43% | 0.00% | 1,037,238 | 122,208 | 13.36% | 1,011,203 | Jun 30, 2024 |
| PFM HEALTH SCIENCES, LP | 4.35% | 0.51% | 10,520,231 | 97,096 | 0.93% | 10,256,173 | Jun 30, 2024 |
| LPL FINANCIAL LLC | 0.08% | 0.00% | 198,856 | 90,000 | 82.68% | 193,865 | Jun 30, 2024 |
| VIRTU FINANCIAL LLC | 0.03% | 0.01% | 79,239 | 79,239 | 100.00% | 77,000 | Jun 30, 2024 |
| STATE STREET CORP | 0.16% | - | 390,901 | 78,363 | 25.07% | 381,089,000 | Jun 30, 2024 |
| MORGAN STANLEY | 0.18% | - | 440,832 | 67,551 | 18.10% | 429,768 | Jun 30, 2024 |
| INVESCO LTD. | 0.01% | - | 34,743 | 34,743 | 100.00% | 33,871 | Jun 30, 2024 |
| COLUMBIA ADVISORY PARTNERS LLC | 0.01% | 0.03% | 28,087 | 12,502 | 80.22% | 27,382 | Jun 30, 2024 |
| GROUP ONE TRADING, L.P. | 0.01% | 0.00% | 34,037 | 11,670 | 52.18% | 33,183,000 | Jun 30, 2024 |
| BAADER BANK AKTIENGESELLSCHAFT | 0.00% | 0.00% | 10,287 | 10,287 | 100.00% | 8,167 | Jun 30, 2024 |
| RAYMOND JAMES & ASSOCIATES | 0.00% | - | 10,218 | 10,218 | 100.00% | 9,962 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.01% | - | 16,721 | 9,599 | 134.78% | 16,299 | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | 0.03% | - | 63,672 | 9,500 | 17.54% | 62,074 | Jun 30, 2024 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.01% | - | 20,195 | 3,849 | 23.55% | 20,000 | Jun 30, 2024 |
| STIFEL FINANCIAL CORP | 0.01% | - | 27,619 | 3,822 | 16.06% | 26,927 | Jun 30, 2024 |
| IFP ADVISORS, INC | 0.00% | 0.00% | 3,023 | 3,023 | 100.00% | 2,947 | Jun 30, 2024 |
| ACUITAS INVESTMENTS, LLC | 0.22% | 0.28% | 541,201 | 2,880 | 0.54% | 527,617 | Jun 30, 2024 |
As of Jun 30 2024, Adaptimmune Therapeutics's largest institutional buyer is LONG FOCUS CAPITAL MANAGEMENT, LLC. The company purchased 1.66M stocks of ADAP, valued at $12.04M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 0.97% | 0.03% | 2,343,695 | -8,443,327 | -78.27% | 2,284,868 | Jun 30, 2024 |
| BAILLIE GIFFORD & CO | 6.26% | 0.01% | 15,149,203 | -722,672 | -4.55% | 14,768,958 | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | - | - | - | -675,882 | -100.00% | - | Jun 30, 2024 |
| GSA CAPITAL PARTNERS LLP | - | - | - | -370,179 | -100.00% | - | Jun 30, 2024 |
| UBS GROUP AG | 0.00% | - | 1,817 | -194,879 | -99.08% | 1,772 | Jun 30, 2024 |
| HARBOR CAPITAL ADVISORS, INC. | - | - | - | -188,070 | -100.00% | - | Jun 30, 2024 |
| MARSHALL WACE, LLP | 0.06% | 0.00% | 144,880 | -109,133 | -42.96% | 140,534 | Jun 30, 2024 |
| BLACKROCK INC. | 0.08% | - | 193,757 | -95,931 | -33.12% | 188,894 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.01% | - | 16,119 | -91,443 | -85.01% | 15,714 | Jun 30, 2024 |
| CIBC PRIVATE WEALTH GROUP, LLC | 0.00% | - | 3,023 | -73,698 | -96.06% | 3,507 | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | - | - | - | -67,665 | -100.00% | - | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.32% | 0.00% | 779,615 | -45,564 | -5.52% | 760,047 | Jun 30, 2024 |
| FMR LLC | 0.70% | 0.00% | 1,690,481 | -42,084 | -2.43% | 1,648,050 | Jun 30, 2024 |
| CAPTRUST FINANCIAL ADVISORS | 0.03% | 0.00% | 83,041 | -28,911 | -25.82% | 80,957 | Jun 30, 2024 |
| BALLENTINE PARTNERS, LLC | - | - | - | -14,489 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -14,474 | -100.00% | - | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 1.92% | 0.00% | 4,653,325 | -14,462 | -0.31% | 4,532,338 | Jun 30, 2024 |
| PROCYON ADVISORS, LLC | - | - | - | -13,000 | -100.00% | - | Jun 30, 2024 |
| ATOM INVESTORS LP | - | - | - | -10,510 | -100.00% | - | Jun 30, 2024 |
| VONTOBEL HOLDING LTD. | 0.01% | - | 13,000 | -10,000 | -43.48% | 12,640 | Jun 30, 2024 |
As of Jun 30 2024, Adaptimmune Therapeutics's biggest institutional seller is BAKER BROS. ADVISORS LP. The company sold -8.44M shares of ADAP, valued at $2.28M.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| INVESCO LTD. | 0.01% | - | 34,743 | 34,743 | 100.00% | 33,871 | Jun 30, 2024 |
| BAADER BANK AKTIENGESELLSCHAFT | 0.00% | 0.00% | 10,287 | 10,287 | 100.00% | 8,167 | Jun 30, 2024 |
| IFP ADVISORS, INC | 0.00% | 0.00% | 3,023 | 3,023 | 100.00% | 2,947 | Jun 30, 2024 |
| PARALLEL ADVISORS, LLC | 0.00% | - | 250 | 250 | 100.00% | 244 | Jun 30, 2024 |
Adaptimmune Therapeutics's largest new institutional shareholder by number of shares is INVESCO LTD., purchased 34.74K shares, valued at $33.87K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CUBIST SYSTEMATIC STRATEGIES, LLC | - | - | - | -675,882 | -100.00% | - | Jun 30, 2024 |
| GSA CAPITAL PARTNERS LLP | - | - | - | -370,179 | -100.00% | - | Jun 30, 2024 |
| HARBOR CAPITAL ADVISORS, INC. | - | - | - | -188,070 | -100.00% | - | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | - | - | - | -67,665 | -100.00% | - | Jun 30, 2024 |
| BALLENTINE PARTNERS, LLC | - | - | - | -14,489 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -14,474 | -100.00% | - | Jun 30, 2024 |
| PROCYON ADVISORS, LLC | - | - | - | -13,000 | -100.00% | - | Jun 30, 2024 |
| ATOM INVESTORS LP | - | - | - | -10,510 | -100.00% | - | Jun 30, 2024 |
| SIGNATUREFD, LLC | - | - | - | -2,037 | -100.00% | - | Jun 30, 2024 |
| ROYAL BANK OF CANADA | - | - | - | -700 | -100.00% | - | Jun 30, 2024 |
Adaptimmune Therapeutics's largest sold out institutional shareholder by shares sold is CUBIST SYSTEMATIC STRATEGIES, LLC, sold -0.68M shares, valued at -, as of undefined.
Adaptimmune Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| VICTORY VARIABLE INSURANCE FUNDS | 0.14% | 69,490 | - | - | Mar 31, 2024 |
| SMALLCAP WORLD FUND INC | 0.11% | 8,002,700 | - | - | Mar 31, 2024 |
| TEKLA LIFE SCIENCES INVESTORS | 0.08% | 37,187 | - | - | Mar 31, 2024 |
| AdvisorShares Trust | 0.05% | 216,299 | - | - | Mar 28, 2024 |
| VICTORY PORTFOLIOS | 0.05% | 1,662,020 | - | - | Mar 31, 2024 |
| Tekla World Healthcare Fund | 0.03% | 39,874 | - | - | Mar 31, 2024 |
| ETFis Series Trust I | 0.03% | 44,300 | - | - | Jan 31, 2024 |
| LORD ABBETT SECURITIES TRUST | 0.03% | 141,129 | - | - | Jan 31, 2024 |
| Fidelity Commonwealth Trust II | 0.01% | 99,822 | 99,822 | - | Aug 31, 2023 |
| Listed Funds Trust | 0.01% | 57,424 | - | - | Mar 31, 2024 |
| OLD WESTBURY FUNDS INC | 0.01% | 1,485,464 | -913,554 | -38.08% | Jan 31, 2024 |
| Harbor ETF Trust | 0.01% | 42,608 | -1,661 | -3.75% | Jan 31, 2024 |
| ALPS ETF Trust | 0.01% | 102,308 | - | - | Feb 29, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.01% | 491,600 | - | - | Feb 29, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.01% | 19,240 | - | - | Feb 29, 2024 |
| FIDELITY COVINGTON TRUST | 0.01% | 98,680 | -1,142 | -1.14% | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 54,536 | - | - | Mar 31, 2024 |
| HARBOR FUNDS | 0.00% | 100,142 | -5,449 | -5.16% | Jan 31, 2024 |
| Direxion Shares ETF Trust | 0.00% | 532,188 | - | - | Jan 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 73,922 | - | - | Feb 29, 2024 |
| Simplify Exchange Traded Funds | 0.00% | 150,000 | - | - | Mar 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 492,007 | - | - | Jan 31, 2024 |
| SPDR INDEX SHARES FUNDS | 0.00% | 304,038 | 77,683 | 34.32% | Mar 31, 2024 |
| BAILLIE GIFFORD FUNDS | 0.00% | 7,284 | - | - | Mar 28, 2024 |
| LoCorr Investment Trust | 0.00% | 16,257 | - | - | Mar 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 117,909 | - | - | Feb 29, 2024 |
| Catholic Responsible Investments Funds | 0.00% | 17,099 | 17,099 | - | Jan 31, 2023 |
| VALIC Co I | 0.00% | 75,650 | - | - | Feb 29, 2024 |
| TRUST FOR PROFESSIONAL MANAGERS | 0.00% | 82,961 | 64,398 | 346.92% | Feb 29, 2024 |
| ETF Series Solutions | 0.00% | 3,736 | - | - | Jan 31, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 46,532 | - | - | Jan 31, 2024 |
| NORTHERN FUNDS | 0.00% | 20,820 | - | - | Mar 28, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 6,958 | - | - | Mar 31, 2024 |
| ADVANCED SERIES TRUST | 0.00% | 197,850 | - | - | Mar 28, 2024 |
| iSHARES TRUST | 0.00% | 964,496 | - | - | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 68,561 | - | - | Mar 31, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 16,913 | - | - | Jan 31, 2024 |
| PROSHARES TRUST | 0.00% | 13,136 | - | - | Feb 29, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 273 | - | - | Feb 29, 2024 |
| PACIFIC FUNDS SERIES TRUST | 0.00% | 13,000 | - | - | Mar 31, 2023 |
| WILSHIRE MUTUAL FUNDS INC | 0.00% | 10,080 | - | - | Dec 31, 2023 |
| PACIFIC SELECT FUND | 0.00% | 100,000 | - | - | Mar 31, 2024 |
| MUTUAL FUND SERIES TRUST | 0.00% | 68,500 | - | - | Mar 31, 2024 |
| EMPOWER FUNDS, INC. | 0.00% | 11,579 | - | - | Mar 31, 2024 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 25,396 | - | - | Dec 31, 2023 |
| SPDR SERIES TRUST | 0.00% | 277,475 | - | - | Mar 31, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 2,432 | - | - | Mar 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 1,558 | - | - | Mar 31, 2024 |
Adaptimmune Therapeutics's largest mutual fund holder by % of total assets is "VICTORY VARIABLE INSURANCE FUNDS", owning 69.49K shares, compromising 0.14% of its total assets.
Adaptimmune Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 75 | -9.64% |
| 31 Mar, 24 | 83 | 10.67% |
| 31 Dec, 23 | 75 | -1.32% |
| 30 Sep, 23 | 76 | -11.63% |
| 30 Jun, 23 | 86 | 30.30% |
| 31 Mar, 23 | 66 | -4.35% |
| 31 Dec, 22 | 69 | 2.99% |
| 30 Sep, 22 | 67 | -10.67% |
| 30 Jun, 22 | 75 | -5.06% |
| 31 Mar, 22 | 79 | -10.23% |
| 31 Dec, 21 | 88 | -7.37% |
| 30 Sep, 21 | 95 | 10.47% |
| 30 Jun, 21 | 86 | -1.15% |
| 31 Mar, 21 | 87 | -4.40% |
| 31 Dec, 20 | 91 | 13.75% |
| 30 Sep, 20 | 80 | -6.98% |
| 30 Jun, 20 | 86 | 75.51% |
| 31 Mar, 20 | 49 | 32.43% |
| 31 Dec, 19 | 37 | -15.91% |
| 30 Sep, 19 | 44 | -22.81% |
| 30 Jun, 19 | 57 | -14.93% |
| 31 Mar, 19 | 67 | -17.28% |
| 31 Dec, 18 | 81 | -18.18% |
| 30 Sep, 18 | 99 | 8.79% |
| 30 Jun, 18 | 91 | 12.35% |
| 31 Mar, 18 | 81 | 12.50% |
| 31 Dec, 17 | 72 | 7.46% |
| 30 Sep, 17 | 67 | 24.07% |
| 30 Jun, 17 | 54 | 10.20% |
| 31 Mar, 17 | 49 | 22.50% |
| 31 Dec, 16 | 40 | -13.04% |
| 30 Sep, 16 | 46 | -2.13% |
| 30 Jun, 16 | 47 | -2.08% |
| 31 Mar, 16 | 48 | - |
| 31 Dec, 15 | 48 | 17.07% |
| 30 Sep, 15 | 41 | -8.89% |
| 30 Jun, 15 | 45 | - |
As of 30 Jun 24, 75 institutions are holding Adaptimmune Therapeutics's shares, representing a decrease of -9.64% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 153,495,933 | -5.30% |
| 31 Mar, 24 | 162,089,971 | 12.87% |
| 31 Dec, 23 | 143,609,094 | -3.14% |
| 30 Sep, 23 | 148,268,772 | 2.49% |
| 30 Jun, 23 | 144,661,851 | 24.75% |
| 31 Mar, 23 | 115,962,408 | 1.77% |
| 31 Dec, 22 | 113,940,922 | 0.06% |
| 30 Sep, 22 | 113,867,602 | -0.68% |
| 30 Jun, 22 | 114,649,922 | 4.17% |
| 31 Mar, 22 | 110,055,608 | -3.11% |
| 31 Dec, 21 | 113,588,535 | 1.84% |
| 30 Sep, 21 | 111,534,559 | -0.03% |
| 30 Jun, 21 | 111,571,973 | -4.90% |
| 31 Mar, 21 | 117,325,119 | -0.58% |
| 31 Dec, 20 | 118,004,626 | -9.01% |
| 30 Sep, 20 | 129,696,677 | 1.21% |
| 30 Jun, 20 | 128,142,503 | 36.55% |
| 31 Mar, 20 | 93,844,790 | 44.65% |
| 31 Dec, 19 | 64,875,550 | -4.75% |
| 30 Sep, 19 | 68,108,115 | -0.14% |
| 30 Jun, 19 | 68,203,831 | -1.73% |
| 31 Mar, 19 | 69,407,592 | 0.42% |
| 31 Dec, 18 | 69,114,095 | 5.48% |
| 30 Sep, 18 | 65,525,171 | 16.99% |
| 30 Jun, 18 | 56,010,665 | -0.29% |
| 31 Mar, 18 | 56,173,620 | 7.88% |
| 31 Dec, 17 | 52,069,958 | 2.48% |
| 30 Sep, 17 | 50,808,897 | 5.53% |
| 30 Jun, 17 | 48,145,036 | 21.07% |
| 31 Mar, 17 | 39,767,615 | 33.37% |
| 31 Dec, 16 | 29,817,599 | -3.69% |
| 30 Sep, 16 | 30,960,022 | -3.04% |
| 30 Jun, 16 | 31,929,906 | -0.24% |
| 31 Mar, 16 | 32,005,799 | 53.80% |
| 31 Dec, 15 | 20,810,197 | 37.25% |
| 30 Sep, 15 | 15,161,960 | -27.63% |
| 30 Jun, 15 | 20,950,250 | - |
Adaptimmune Therapeutics (ADAP) has 153.50M shares outstanding as of 30 Jun 24, down -5.30% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 63.46% | 1.25% |
| 31 Mar, 24 | 71.37% | 0.64% |
| 31 Dec, 23 | 105.76% | 1.64% |
| 30 Sep, 23 | 80.28% | 1.05% |
| 30 Jun, 23 | 87.56% | 1.78% |
| 31 Mar, 23 | 70.19% | 1.40% |
| 31 Dec, 22 | 70.68% | 1.46% |
| 30 Sep, 22 | 69.66% | 1.36% |
| 30 Jun, 22 | 71.45% | 1.45% |
| 31 Mar, 22 | 70.25% | 1.32% |
| 31 Dec, 21 | 72.90% | 1.43% |
| 30 Sep, 21 | 71.45% | 1.39% |
| 30 Jun, 21 | 71.66% | 1.25% |
| 31 Mar, 21 | 75.61% | 1.30% |
| 31 Dec, 20 | 76.24% | 1.08% |
| 30 Sep, 20 | 83.85% | 0.96% |
| 30 Jun, 20 | 93.45% | 1.61% |
| 31 Mar, 20 | 76.12% | 1.99% |
| 31 Dec, 19 | 61.81% | 1.47% |
| 30 Sep, 19 | 64.78% | 1.53% |
| 30 Jun, 19 | 65.02% | 1.48% |
| 31 Mar, 19 | 66.32% | 1.32% |
| 31 Dec, 18 | 70.97% | 1.56% |
| 30 Sep, 18 | 67.55% | 1.91% |
| 30 Jun, 18 | 59.46% | 1.66% |
| 31 Mar, 18 | 59.93% | 1.94% |
| 31 Dec, 17 | 55.58% | 1.88% |
| 30 Sep, 17 | 54.32% | 2.02% |
| 30 Jun, 17 | 51.88% | 1.68% |
| 31 Mar, 17 | 55.62% | 3.13% |
| 31 Dec, 16 | 42.12% | 2.20% |
| 30 Sep, 16 | 43.74% | 2.15% |
| 30 Jun, 16 | 45.11% | 2.21% |
| 31 Mar, 16 | 45.22% | 5.23% |
| 31 Dec, 15 | 29.40% | 6.41% |
| 30 Sep, 15 | 21.42% | 1.43% |
| 30 Jun, 15 | 38.68% | - |
As of 30 Jun 24, Adaptimmune Therapeutics is held by 63.46% institutional shareholders, representing a 1.25% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 22 | -37.14% |
| 31 Mar, 24 | 35 | 25.00% |
| 31 Dec, 23 | 28 | 27.27% |
| 30 Sep, 23 | 22 | -60.71% |
| 30 Jun, 23 | 56 | 133.33% |
| 31 Mar, 23 | 24 | -20.00% |
| 31 Dec, 22 | 30 | - |
| 30 Sep, 22 | 30 | 11.11% |
| 30 Jun, 22 | 27 | -27.03% |
| 31 Mar, 22 | 37 | 12.12% |
| 31 Dec, 21 | 33 | -31.25% |
| 30 Sep, 21 | 48 | 33.33% |
| 30 Jun, 21 | 36 | -12.20% |
| 31 Mar, 21 | 41 | -25.45% |
| 31 Dec, 20 | 55 | 30.95% |
| 30 Sep, 20 | 42 | -30.00% |
| 30 Jun, 20 | 60 | 100.00% |
| 31 Mar, 20 | 30 | 87.50% |
| 31 Dec, 19 | 16 | 6.67% |
| 30 Sep, 19 | 15 | -11.76% |
| 30 Jun, 19 | 17 | -41.38% |
| 31 Mar, 19 | 29 | -30.95% |
| 31 Dec, 18 | 42 | 23.53% |
| 30 Sep, 18 | 34 | -20.93% |
| 30 Jun, 18 | 43 | -4.44% |
| 31 Mar, 18 | 45 | 25.00% |
| 31 Dec, 17 | 36 | -12.20% |
| 30 Sep, 17 | 41 | 86.36% |
| 30 Jun, 17 | 22 | -24.14% |
| 31 Mar, 17 | 29 | 81.25% |
| 31 Dec, 16 | 16 | -11.11% |
| 30 Sep, 16 | 18 | 20.00% |
| 30 Jun, 16 | 15 | -37.50% |
| 31 Mar, 16 | 24 | -38.46% |
| 31 Dec, 15 | 39 | 160.00% |
| 30 Sep, 15 | 15 | -66.67% |
| 30 Jun, 15 | 45 | - |
22 institutional shareholders have increased their position in ADAP stock as of 30 Jun 24 compared to 35 in the previous quarter (a -37.14% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 20 | -9.09% |
| 31 Mar, 24 | 22 | -12.00% |
| 31 Dec, 23 | 25 | 4.17% |
| 30 Sep, 23 | 24 | 118.18% |
| 30 Jun, 23 | 11 | -35.29% |
| 31 Mar, 23 | 17 | -22.73% |
| 31 Dec, 22 | 22 | 46.67% |
| 30 Sep, 22 | 15 | -31.82% |
| 30 Jun, 22 | 22 | -4.35% |
| 31 Mar, 22 | 23 | -28.13% |
| 31 Dec, 21 | 32 | 52.38% |
| 30 Sep, 21 | 21 | - |
| 30 Jun, 21 | 21 | - |
| 31 Mar, 21 | 21 | 16.67% |
| 31 Dec, 20 | 18 | -14.29% |
| 30 Sep, 20 | 21 | 90.91% |
| 30 Jun, 20 | 11 | 10.00% |
| 31 Mar, 20 | 10 | 25.00% |
| 31 Dec, 19 | 8 | -27.27% |
| 30 Sep, 19 | 11 | -42.11% |
| 30 Jun, 19 | 19 | 18.75% |
| 31 Mar, 19 | 16 | -23.81% |
| 31 Dec, 18 | 21 | -44.74% |
| 30 Sep, 18 | 38 | 40.74% |
| 30 Jun, 18 | 27 | 42.11% |
| 31 Mar, 18 | 19 | 11.76% |
| 31 Dec, 17 | 17 | 30.77% |
| 30 Sep, 17 | 13 | - |
| 30 Jun, 17 | 13 | 85.71% |
| 31 Mar, 17 | 7 | -30.00% |
| 31 Dec, 16 | 10 | -9.09% |
| 30 Sep, 16 | 11 | -21.43% |
| 30 Jun, 16 | 14 | 133.33% |
| 31 Mar, 16 | 6 | 200.00% |
| 31 Dec, 15 | 2 | -84.62% |
| 30 Sep, 15 | 13 | - |
| 30 Jun, 15 | - | - |
20 institutional shareholders have reduced their position in ADAP stock as of 30 Jun 24 compared to 22 in the previous quarter (a -9.09% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 75 | -9.64% | 153,495,933 | -5.30% | 63.46% | 1.25% | 22 | -37.14% | 20 | -9.09% |
| 31 Mar, 24 | 83 | 10.67% | 162,089,971 | 12.87% | 71.37% | 0.64% | 35 | 25.00% | 22 | -12.00% |
| 31 Dec, 23 | 75 | -1.32% | 143,609,094 | -3.14% | 105.76% | 1.64% | 28 | 27.27% | 25 | 4.17% |
| 30 Sep, 23 | 76 | -11.63% | 148,268,772 | 2.49% | 80.28% | 1.05% | 22 | -60.71% | 24 | 118.18% |
| 30 Jun, 23 | 86 | 30.30% | 144,661,851 | 24.75% | 87.56% | 1.78% | 56 | 133.33% | 11 | -35.29% |
| 31 Mar, 23 | 66 | -4.35% | 115,962,408 | 1.77% | 70.19% | 1.40% | 24 | -20.00% | 17 | -22.73% |
| 31 Dec, 22 | 69 | 2.99% | 113,940,922 | 0.06% | 70.68% | 1.46% | 30 | - | 22 | 46.67% |
| 30 Sep, 22 | 67 | -10.67% | 113,867,602 | -0.68% | 69.66% | 1.36% | 30 | 11.11% | 15 | -31.82% |
| 30 Jun, 22 | 75 | -5.06% | 114,649,922 | 4.17% | 71.45% | 1.45% | 27 | -27.03% | 22 | -4.35% |
| 31 Mar, 22 | 79 | -10.23% | 110,055,608 | -3.11% | 70.25% | 1.32% | 37 | 12.12% | 23 | -28.13% |
| 31 Dec, 21 | 88 | -7.37% | 113,588,535 | 1.84% | 72.90% | 1.43% | 33 | -31.25% | 32 | 52.38% |
| 30 Sep, 21 | 95 | 10.47% | 111,534,559 | -0.03% | 71.45% | 1.39% | 48 | 33.33% | 21 | - |
| 30 Jun, 21 | 86 | -1.15% | 111,571,973 | -4.90% | 71.66% | 1.25% | 36 | -12.20% | 21 | - |
| 31 Mar, 21 | 87 | -4.40% | 117,325,119 | -0.58% | 75.61% | 1.30% | 41 | -25.45% | 21 | 16.67% |
| 31 Dec, 20 | 91 | 13.75% | 118,004,626 | -9.01% | 76.24% | 1.08% | 55 | 30.95% | 18 | -14.29% |
| 30 Sep, 20 | 80 | -6.98% | 129,696,677 | 1.21% | 83.85% | 0.96% | 42 | -30.00% | 21 | 90.91% |
| 30 Jun, 20 | 86 | 75.51% | 128,142,503 | 36.55% | 93.45% | 1.61% | 60 | 100.00% | 11 | 10.00% |
| 31 Mar, 20 | 49 | 32.43% | 93,844,790 | 44.65% | 76.12% | 1.99% | 30 | 87.50% | 10 | 25.00% |
| 31 Dec, 19 | 37 | -15.91% | 64,875,550 | -4.75% | 61.81% | 1.47% | 16 | 6.67% | 8 | -27.27% |
| 30 Sep, 19 | 44 | -22.81% | 68,108,115 | -0.14% | 64.78% | 1.53% | 15 | -11.76% | 11 | -42.11% |
| 30 Jun, 19 | 57 | -14.93% | 68,203,831 | -1.73% | 65.02% | 1.48% | 17 | -41.38% | 19 | 18.75% |
| 31 Mar, 19 | 67 | -17.28% | 69,407,592 | 0.42% | 66.32% | 1.32% | 29 | -30.95% | 16 | -23.81% |
| 31 Dec, 18 | 81 | -18.18% | 69,114,095 | 5.48% | 70.97% | 1.56% | 42 | 23.53% | 21 | -44.74% |
| 30 Sep, 18 | 99 | 8.79% | 65,525,171 | 16.99% | 67.55% | 1.91% | 34 | -20.93% | 38 | 40.74% |
| 30 Jun, 18 | 91 | 12.35% | 56,010,665 | -0.29% | 59.46% | 1.66% | 43 | -4.44% | 27 | 42.11% |
| 31 Mar, 18 | 81 | 12.50% | 56,173,620 | 7.88% | 59.93% | 1.94% | 45 | 25.00% | 19 | 11.76% |
| 31 Dec, 17 | 72 | 7.46% | 52,069,958 | 2.48% | 55.58% | 1.88% | 36 | -12.20% | 17 | 30.77% |
| 30 Sep, 17 | 67 | 24.07% | 50,808,897 | 5.53% | 54.32% | 2.02% | 41 | 86.36% | 13 | - |
| 30 Jun, 17 | 54 | 10.20% | 48,145,036 | 21.07% | 51.88% | 1.68% | 22 | -24.14% | 13 | 85.71% |
| 31 Mar, 17 | 49 | 22.50% | 39,767,615 | 33.37% | 55.62% | 3.13% | 29 | 81.25% | 7 | -30.00% |
| 31 Dec, 16 | 40 | -13.04% | 29,817,599 | -3.69% | 42.12% | 2.20% | 16 | -11.11% | 10 | -9.09% |
| 30 Sep, 16 | 46 | -2.13% | 30,960,022 | -3.04% | 43.74% | 2.15% | 18 | 20.00% | 11 | -21.43% |
| 30 Jun, 16 | 47 | -2.08% | 31,929,906 | -0.24% | 45.11% | 2.21% | 15 | -37.50% | 14 | 133.33% |
| 31 Mar, 16 | 48 | - | 32,005,799 | 53.80% | 45.22% | 5.23% | 24 | -38.46% | 6 | 200.00% |
| 31 Dec, 15 | 48 | 17.07% | 20,810,197 | 37.25% | 29.40% | 6.41% | 39 | 160.00% | 2 | -84.62% |
| 30 Sep, 15 | 41 | -8.89% | 15,161,960 | -27.63% | 21.42% | 1.43% | 15 | -66.67% | 13 | - |
| 30 Jun, 15 | 45 | - | 20,950,250 | - | 38.68% | - | 45 | - | - | - |
Adaptimmune Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Adaptimmune Therapeutics's stock was made by Piccina Cintia on Jun 18 2024, selling 24,531 shares at $0.93 per share (valued at $22.81K).
Adaptimmune Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 8 | - | - |
| Q2 2024 | - | 1 | - |
| Q1 2024 | 18 | 19 | 94.74% |
| Q4 2023 | - | 1 | - |
| Q3 2023 | 24 | 3 | 800.00% |
| Q2 2023 | 3 | 1 | 300.00% |
| Q1 2023 | 23 | 17 | 135.29% |
| Q3 2022 | 14 | 4 | 350.00% |
| Q2 2022 | 2 | 1 | 200.00% |
| Q1 2022 | 15 | 16 | 93.75% |
| Q3 2021 | 8 | 4 | 200.00% |
| Q2 2021 | 1 | 1 | 100.00% |
| Q1 2021 | 13 | 11 | 118.18% |
| Q4 2020 | 2 | - | - |
| Q3 2020 | 8 | 4 | 200.00% |
| Q2 2020 | 5 | 1 | 500.00% |
| Q1 2020 | 16 | 19 | 84.21% |
| Q4 2019 | - | - | - |
| Q3 2019 | 12 | 9 | 133.33% |
| Q2 2019 | 3 | - | - |
8 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Adaptimmune Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | - | - |
| Q2 2024 | - | 1 | - |
| Q1 2024 | - | 19 | - |
| Q4 2023 | - | - | - |
| Q3 2023 | - | 3 | - |
| Q2 2023 | - | 1 | - |
| Q1 2023 | - | 17 | - |
| Q3 2022 | - | 4 | - |
| Q2 2022 | 1 | 1 | 100.00% |
| Q1 2022 | - | 16 | - |
| Q3 2021 | - | 4 | - |
| Q2 2021 | 1 | 1 | 100.00% |
| Q1 2021 | - | 11 | - |
| Q4 2020 | 2 | - | - |
| Q3 2020 | - | 4 | - |
| Q2 2020 | 2 | 1 | 200.00% |
| Q1 2020 | 6 | 11 | 54.55% |
| Q4 2019 | - | - | - |
| Q3 2019 | - | 1 | - |
| Q2 2019 | - | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Adaptimmune Therapeutics's stocks.
Adaptimmune Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| PLRX | Pliant Therapeutics, Inc. |
| MREO | Mereo BioPharma Group plc |
| PDSB | PDS Biotechnology Corporation |
| STOK | Stoke Therapeutics, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| CRVS | Corvus Pharmaceuticals, Inc. |
| APTO | Aptose Biosciences Inc. |
| SGMO | Sangamo Therapeutics, Inc. |
| AFMD | Affimed N.V. |
| AGIO | Agios Pharmaceuticals, Inc. |
| INKT | MiNK Therapeutics, Inc. |
| NKTX | Nkarta, Inc. |
| LPTX | Leap Therapeutics, Inc. |
| PIRS | Pieris Pharmaceuticals, Inc. |
| ACET | Adicet Bio, Inc. |
| FIXX | Q32 Bio Inc. |
ADAP Ownership FAQ
Who Owns Adaptimmune Therapeutics?
Adaptimmune Therapeutics is owned by institutional shareholders (63.46%), insiders (0.38%), and public (36.16%). The largest institutional shareholder of Adaptimmune Therapeutics is MATRIX CAPITAL MANAGEMENT COMPANY, LP (16.11% of total shares) and the top mutual fund owner is VICTORY VARIABLE INSURANCE FUNDS (0.14% of total shares).
Who are the major institutional shareholders of Adaptimmune Therapeutics?
Adaptimmune Therapeutics's major institutional shareholders are MATRIX CAPITAL MANAGEMENT COMPANY, LP, ECOR1 CAPITAL, LLC, NEA MANAGEMENT COMPANY, LLC, BAILLIE GIFFORD & CO, and LONG FOCUS CAPITAL MANAGEMENT, LLC. The top five shareholders own together 45.87% of the company's share outstanding.
How many Adaptimmune Therapeutics shareholders are there?
As of Jun 2024, there are 75 institutional shareholders of Adaptimmune Therapeutics.
What percentage of Adaptimmune Therapeutics is owned by MATRIX CAPITAL MANAGEMENT COMPANY, LP?
MATRIX CAPITAL MANAGEMENT COMPANY, LP owns 38.97M shares of Adaptimmune Therapeutics, representing 16.11% of the company's total shares outstanding, valued at $38M (as of Jun 2024).
What percentage of Adaptimmune Therapeutics is owned by ECOR1 CAPITAL, LLC?
As of Jun 2024, ECOR1 CAPITAL, LLC holds 27.4M shares of Adaptimmune Therapeutics (ADAP), compromising 11.33% of the company, valued at $26.72M.
What percentage of Adaptimmune Therapeutics is owned by NEA MANAGEMENT COMPANY, LLC?
NEA MANAGEMENT COMPANY, LLC is the third largest holder of Adaptimmune Therapeutics. The company owns 17.08M of the company's shares outstanding (worth $16.65M).